Account
Publications
15.10.2024
WODC Europe 2024: Are NICE Achieving Their Timelin...

AUTHORS: Amrit Kaliasethi, Tia Kwong, Mariam Bibi OBJECTIVES  In 2013, England’s National Ins...

Read more
Publications
15.10.2024
WODC Europe 2024: Comparing And Contrasting Early ...

AUTHORS: Amy Boyers, Solen Monteil, Mariam Bibi OBJECTIVES  Early Access Programmes (EAPs) prov...

Read more
Articles
28.08.2024
How to integrate Market Access strategy with evide...

Introduction What is the secret to a successful drug launch? One crucial factor is establishing a cr...

Read more
Publications
22.08.2024
ISPOR Europe 2024: Can Patient Involvement Help Op...

We explore whether including the patient voice in early stages of drug development optimises patient...

Read more
Articles
20.08.2024
Adapting to the EU HTA: how to restructure your Ma...

Our latest article discusses key strategies for pharma manufacturers' commercial readiness for EU HT...

Read more
07.08.2024
What does the right market access organisation str...

Effective pricing and market access (PMA) teams are vital for pharmaceutical companies to secure rei...

Read more
Insider Insights
12.06.2024
Scotland leads the UK in approving Mounjaro for ob...

Scottish Medicines Consortium approves the use of obesity treatment under the NHS in UK first, whils...

Read more
Case Studies
02.04.2024
Securing the optimum launch price for a novel phar...

Looking to enhance your market access capabilities? Remap Consulting are the partner to help you lau...

Read more
News
13.02.2024
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more
Articles
08.02.2024
Is the attractiveness of launch in the UK changing...

This expert article focusses on the new proportionate approach, and the international recognition pr...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.